FDA Requests Labeling Change for Asthma Drugs

The U.S. Food and Drug Administration today provided further updated safety information on a class of asthma drugs known as leukotriene modifiers. The FDA has requested that manufacturers include a precaution in the drug prescribing information (drug labeling) regarding neuropsychiatric events (behavior, mood changes) that have been reported in some persons taking montelukast (Singulair), zafirlukast (Accolate), and zileuton (Zyflo and Zyflo CR).

Leukotrienes are chemicals the body releases in response to an inflammatory stimulus, such as when a person breathes in an allergen. Montelukast and zafirlukast are leukotriene receptor antagonists that work by blocking leukotrienes. Zileuton is a leukotriene synthesis inhibitor which works by stopping the formation of certain substances that cause swelling, tightening, and mucus production in the airways.

Legal Help

If you or a loved one has suffered an adverse health event resutling from the use of these products, please click the link below and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.

Please click here for a free evaluation of your case

Last updated on Jun-12-09

LEGAL HELP NOW!

Please complete this form to request a review of your complaint by an attorney.

First name:

Last name:

Email address:

Phone number(s):

State:

Zip Code:

Defendant:

Describe your complaint:

Subscribe to our free newsletter

There is absolutely no cost to you to submit this form. Doing so places you under no obligations and does not establish an attorney-client relationship.

Legal Help Now!

CLICK HERE

Related Lawsuits

Legal Services: